The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of consensus molecular subtyping (CMS) on survival in the CO.26 trial of durvalumab plus tremelimumab versus best supportive care (BSC) in metastatic colorectal cancer (mCRC).
 
Jonathan M. Loree
Consulting or Advisory Role - AMGEN; Bayer; Eisai; Ipsen; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Amgen (Inst); Ipsen (Inst)
 
James T. Topham
No Relationships to Disclose
 
Hagen Fritz Kennecke
Honoraria - Advanced Accelerator Applications; Ipsen
Speakers' Bureau - Advanced Accelerator Applications
Research Funding - Taiho Oncology
 
Harriet Feilotter
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Diaceutics; EMD Serono; Janssen Diagnostics; Novartis Canada Pharmaceuticals Inc; Pfizer; Precision RxDx; Roche Canada
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen Diagnostics; Precision RxDx; Roche Canada
Speakers' Bureau - AstraZeneca; Bayer; EMD Serono
Research Funding - AstraZeneca (Inst); Bayer (Inst); Delphi Diagnostics (Inst); EMD Serono (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen Diagnostics; Roche Canada; Thermo Fisher Scientific
 
Young S Lee
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Shakeel Virk
No Relationships to Disclose
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Iylon; Lutris; MolecularMatch
Consulting or Advisory Role - Abbvie; Amal Therapeutics; AstraZeneca/MedImmune; Bayer Health; Bicara Therapeutics; Boehringer Ingelheim; Boston Biomedical; Carina Biotech; Daiichi Sankyo; EMD Serono; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Frontier Medicines; Genentech; Genomic Health; Gilead Sciences; GlaxoSmithKline; HalioDx; Holy Stone Healthcare; Inivata; Ipsen; Iylon; Jacobio; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Lutris; Merck; Mirati Therapeutics; Natera; Novartis; Numab; Pfizer; Pierre Fabre; Redx Pharma; Repare Therapeutics; Replimune; Servier; Taiho Pharmaceutical; Xilis
Research Funding - Amgen; Array BioPharma; Biocartis; Daiichi Sankyo; EMD Serono; Genentech/Roche; Guardant Health; Lilly; MedImmune; Novartis; Sanofi
 
Dzifa Yawa Duose
No Relationships to Disclose
 
Ganiraju C. Manyam
No Relationships to Disclose
 
Jeffrey S Morris
No Relationships to Disclose
 
Dipen M. Maru
Honoraria - GSB Pharma (I)
Research Funding - Daiichi Sankyo/UCB Japan
(OPTIONAL) Uncompensated Relationships - Bristol-Myers Squibb/Medarex
 
Daniel Renouf
Honoraria - Celgene; Ipsen; Roche; SERVIER; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Celgene; SERVIER; Shire; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst)
 
Derek J. Jonker
No Relationships to Disclose
 
Dongsheng Tu
No Relationships to Disclose
 
Christopher J. O'Callaghan
No Relationships to Disclose
 
Eric Xueyu Chen
Honoraria - AstraZeneca Canada; Bayer; Eisai; Ipsen; Roche Canada
Research Funding - 1Globe Health Institute; AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck Sharp & Dohme; Mirati Therapeutics; Novartis; Nubiyota; Repare Therapeutics; Roche Canada